{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:56:09Z","timestamp":1793501769869,"version":"4.5.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with rheumatoid arthritis (RA) are at risk of developing interstitial lung disease (ILD), which is associated with high mortality. Screening tools based on risk factors are needed to decide which patients with RA should be screened for ILD using high-resolution computed tomography (HRCT). The ANCHOR-RA study is a multi-national cross-sectional study that will develop a multivariable model for prediction of RA-ILD, which can be used to inform screening for RA-ILD in clinical practice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Investigators will enrol consecutive patients with RA who have \u2265\u20092 of the following risk factors for RA-ILD: male; current or previous smoker; age\u2009\u2265\u200960 years at RA diagnosis; high-positive rheumatoid factor and\/or anti-cyclic citrullinated peptide (titre\u2009&gt;\u20093 x upper limit of normal); presence or history of certain extra-articular manifestations of RA (vasculitis, Felty\u2019s syndrome, secondary Sj\u00f6gren\u2019s syndrome, cutaneous rheumatoid nodules, serositis, and\/or scleritis\/uveitis); high RA disease activity in the prior 12 months. Patients previously identified as having ILD, or who have had a CT scan in the prior 2 years, will not be eligible. Participants will undergo an HRCT scan at their local site, which will be assessed centrally by two expert radiologists. Data will be collected prospectively on demographic and RA-related characteristics, patient-reported outcomes, comorbidities and pulmonary function. The primary outcomes will be the development of a probability score for RA-ILD, based on a multivariable model incorporating potential risk factors commonly assessed in clinical practice, and an estimate of the prevalence of RA-ILD in the study population. It is planned that 1200 participants will be enrolled at approximately 30 sites in the USA, UK, Germany, France, Italy, Spain.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Data from the ANCHOR-RA study will add to the body of evidence to support recommendations for screening for RA-ILD to improve detection of this important complication of RA and enable early intervention.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>clinicaltrials.gov NCT05855109 (submission date: 3 May 2023).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41927-024-00389-4","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T04:02:23Z","timestamp":1716264143000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Design of ANCHOR-RA: a multi-national cross-sectional study on screening for interstitial lung disease in patients with rheumatoid arthritis"],"prefix":"10.1186","volume":"8","author":[{"given":"Jeffrey A.","family":"Sparks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Dieud\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maria","family":"Hoffmann-Vold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd R","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon LF","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Sambevski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Emery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"issue":"2 Pt 1","key":"389_CR1","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1164\/ajrccm.156.2.9609016","volume":"156","author":"E Gabbay","year":"1997","unstructured":"Gabbay E, Tarala R, Will R, Carroll G, Adler B, Cameron D, Lake FR. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med. 1997;156(2 Pt 1):528\u201335. https:\/\/doi.org\/10.1164\/ajrccm.156.2.9609016.","journal-title":"Am J Respir Crit Care Med"},{"key":"389_CR2","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1136\/thx.56.8.622","volume":"56","author":"JK Dawson","year":"2001","unstructured":"Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax. 2001;56:622\u20137. https:\/\/doi.org\/10.1136\/thx.56.8.622.","journal-title":"Thorax"},{"key":"389_CR3","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1164\/rccm.201411-1950OC","volume":"191","author":"TJ Doyle","year":"2015","unstructured":"Doyle TJ, Patel AS, Hatabu H, Nishino M, Wu G, Osorio JC, et al. Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers. Am J Respir Crit Care Med. 2015;191:1403\u201312. https:\/\/doi.org\/10.1164\/rccm.201411-1950OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"389_CR4","doi-asserted-by":"publisher","first-page":"1024298","DOI":"10.3389\/fmed.2022.1024298","volume":"9","author":"A Denis","year":"2022","unstructured":"Denis A, Henket M, Ernst M, Maes N, Thys M, Regnier C, et al. Progressive fibrosing interstitial lung disease in rheumatoid arthritis: a retrospective study. Front Med (Lausanne). 2022;9:1024298. https:\/\/doi.org\/10.3389\/fmed.2022.1024298.","journal-title":"Front Med (Lausanne)"},{"key":"389_CR5","doi-asserted-by":"publisher","first-page":"e002777","DOI":"10.1136\/rmdopen-2022-002777","volume":"9","author":"K Albrecht","year":"2023","unstructured":"Albrecht K, Strangfeld A, Marschall U, Callhoff J. Interstitial lung disease in rheumatoid arthritis: incidence, prevalence and related drug prescriptions between 2007 and 2020. RMD Open. 2023;9:e002777. https:\/\/doi.org\/10.1136\/rmdopen-2022-002777.","journal-title":"RMD Open"},{"key":"389_CR6","doi-asserted-by":"publisher","unstructured":"Hyldgaard C, Harders S, Blegvad J, Herly M, Masic D, Sof\u00edud\u00f3ttir BK, et al. Clinical and preclinical pulmonary disease in newly diagnosed rheumatoid arthritis: a two-year follow-up study. Scand J Rheumatol. 2023;1\u20138. https:\/\/doi.org\/10.1080\/03009742.2023.2194105.","DOI":"10.1080\/03009742.2023.2194105"},{"key":"389_CR7","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/art.27405","volume":"62","author":"T Bongartz","year":"2010","unstructured":"Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62:1583\u201391. https:\/\/doi.org\/10.1002\/art.27405.","journal-title":"Arthritis Rheum"},{"key":"389_CR8","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1164\/rccm.201004-0622OC","volume":"183","author":"AL Olson","year":"2011","unstructured":"Olson AL, Swigris JJ, Sprunger DB, Fischer A, Fernandez-Perez ER, Solomon J, et al. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med. 2011;183:372\u20138. https:\/\/doi.org\/10.1164\/rccm.201004-0622OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"389_CR9","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1136\/annrheumdis-2017-211138","volume":"76","author":"C Hyldgaard","year":"2017","unstructured":"Hyldgaard C, Hilberg O, Pedersen AB, Ulrichsen SP, L\u00f8kke A, Bendstrup E, Ellingsen T. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis. 2017;76:1700\u20136. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211138.","journal-title":"Ann Rheum Dis"},{"key":"389_CR10","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1093\/rheumatology\/keaa836","volume":"60","author":"JA Sparks","year":"2021","unstructured":"Sparks JA, Jin Y, Cho SK, Vine S, Desai R, Doyle TJ, Kim SC. Prevalence, incidence and cause-specific mortality of rheumatoid arthritis-associated interstitial lung disease among older rheumatoid arthritis patients. Rheumatology (Oxford). 2021;60:3689\u201398. https:\/\/doi.org\/10.1093\/rheumatology\/keaa836.","journal-title":"Rheumatology (Oxford)"},{"key":"389_CR11","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1002\/acr.24856","volume":"74","author":"BF Samhouri","year":"2022","unstructured":"Samhouri BF, Vassallo R, Achenbach SJ, Kronzer VL, Davis JM 3rd, Myasoedova E, Crowson CS. Incidence, risk factors, and mortality of clinical and subclinical rheumatoid arthritis-associated interstitial lung disease: a population-based cohort. Arthritis Care Res (Hoboken). 2022;74:2042\u20139. https:\/\/doi.org\/10.1002\/acr.24856.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"389_CR12","doi-asserted-by":"publisher","first-page":"152187","DOI":"10.1016\/j.semarthrit.2023.152187","volume":"60","author":"HJ Farquhar","year":"2023","unstructured":"Farquhar HJ, Beckert N, Beckert L, Edwards AL, Matteson EL, Frampton C, et al. Survival of adults with rheumatoid arthritis associated interstitial lung disease \u2013 a systematic review and meta-analysis. Semin Arthritis Rheum. 2023;60:152187. https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152187.","journal-title":"Semin Arthritis Rheum"},{"key":"389_CR13","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.semarthrit.2006.03.002","volume":"35","author":"A Balbir-Gurman","year":"2006","unstructured":"Balbir-Gurman A, Yigla M, Nahir AM, Braun-Moscovici Y. Rheumatoid pleural effusion. Semin Arthritis Rheum. 2006;35:368\u201378. https:\/\/doi.org\/10.1016\/j.semarthrit.2006.03.002.","journal-title":"Semin Arthritis Rheum"},{"key":"389_CR14","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.semarthrit.2021.08.005","volume":"51","author":"LW Martin","year":"2021","unstructured":"Martin LW, Prisco LC, Huang W, McDermott G, Shadick NA, Doyle TJ, Sparks JA. Prevalence and risk factors of bronchiectasis in rheumatoid arthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2021;51:1067\u201380. https:\/\/doi.org\/10.1016\/j.semarthrit.2021.08.005.","journal-title":"Semin Arthritis Rheum"},{"key":"389_CR15","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ebiom.2018.01.038","volume":"28","author":"J Jacob","year":"2018","unstructured":"Jacob J, Song JW, Yoon HY, Cross G, Barnett J, Woo WL, et al. Prevalence and effects of emphysema in never-smokers with rheumatoid arthritis interstitial lung disease. EbioMedicine. 2018;28:303\u201310. https:\/\/doi.org\/10.1016\/j.ebiom.2018.01.038.","journal-title":"EbioMedicine"},{"key":"389_CR16","doi-asserted-by":"publisher","first-page":"9184","DOI":"10.1038\/s41598-021-88734-2","volume":"11","author":"E Cano-Jim\u00e9nez","year":"2021","unstructured":"Cano-Jim\u00e9nez E, V\u00e1zquez Rodr\u00edguez T, Mart\u00edn-Robles I, Castillo Villegas D, Juan Garc\u00eda J, Bollo de Miguel E, et al. Diagnostic delay of associated interstitial lung disease increases mortality in rheumatoid arthritis. Sci Rep. 2021;11:9184. https:\/\/doi.org\/10.1038\/s41598-021-88734-2.","journal-title":"Sci Rep"},{"key":"389_CR17","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00296-006-0234-0","volume":"27","author":"F Kanat","year":"2007","unstructured":"Kanat F, Levendoglu F, Teke T. Radiological and functional assessment of pulmonary involvement in the rheumatoid arthritis patients. Rheumatol Int. 2007;27:459\u201366. https:\/\/doi.org\/10.1007\/s00296-006-0234-0.","journal-title":"Rheumatol Int"},{"key":"389_CR18","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1001\/archinternmed.2007.59","volume":"168","author":"BR Gochuico","year":"2008","unstructured":"Gochuico BR, Avila NA, Chow CK, Novero LJ, Wu HP, Ren P, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med. 2008;168:159\u201366. https:\/\/doi.org\/10.1001\/archinternmed.2007.59.","journal-title":"Arch Intern Med"},{"key":"389_CR19","doi-asserted-by":"publisher","first-page":"406927","DOI":"10.1155\/2013\/406927","volume":"2013","author":"J Chen","year":"2013","unstructured":"Chen J, Shi Y, Wang X, Huang H, Ascherman D. Asymptomatic preclinical rheumatoid arthritis-associated interstitial lung disease. Clin Dev Immunol. 2013;2013:406927. https:\/\/doi.org\/10.1155\/2013\/406927.","journal-title":"Clin Dev Immunol"},{"key":"389_CR20","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1093\/rheumatology\/keab552","volume":"61","author":"JJ Solomon","year":"2022","unstructured":"Solomon JJ, Swigris JJ, Kreuter M, Polke M, Aronson K, Hoffmann-Vold AM, Dellaripa PF. The attitudes and practices of physicians caring for patients with rheumatoid arthritis-associated interstitial lung disease: an international survey. Rheumatology (Oxford). 2022;61:1459\u201367. https:\/\/doi.org\/10.1093\/rheumatology\/keab552.","journal-title":"Rheumatology (Oxford)"},{"key":"389_CR21","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e44\u201368. https:\/\/doi.org\/10.1164\/rccm.201807-1255ST.","journal-title":"Am J Respir Crit Care Med"},{"key":"389_CR22","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205:e18\u201347. https:\/\/doi.org\/10.1164\/rccm.202202-0399ST.","journal-title":"Am J Respir Crit Care Med"},{"key":"389_CR23","first-page":"199","volume":"32","author":"FC Moazedi-Fuerst","year":"2014","unstructured":"Moazedi-Fuerst FC, Kielhauser SM, Scheidl S, Tripolt NJ, Lutfi A, Yazdani-Biuki B, et al. Ultrasound screening for interstitial lung disease in rheumatoid arthritis. Clin Exp Rheumatol. 2014;32:199\u2013203.","journal-title":"Clin Exp Rheumatol"},{"key":"389_CR24","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1007\/s10067-021-05655-1","volume":"40","author":"N Mena-V\u00e1zquez","year":"2021","unstructured":"Mena-V\u00e1zquez N, Jimenez-N\u00fa\u00f1ez FG, Godoy-Navarrete FJ, Manrique-Arija S, Aguilar-Hurtado MC, Romero-Barco CM, et al. Utility of pulmonary ultrasound to identify interstitial lung disease in patients with rheumatoid arthritis. Clin Rheumatol. 2021;40:2377\u201385. https:\/\/doi.org\/10.1007\/s10067-021-05655-1.","journal-title":"Clin Rheumatol"},{"key":"389_CR25","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13075-021-02586-9","volume":"23","author":"Y Wang","year":"2021","unstructured":"Wang Y, Chen S, Zheng S, Lin J, Hu S, Zhuang J, et al. The role of lung ultrasound B-lines and serum KL-6 in the screening and follow-up of rheumatoid arthritis patients for an identification of interstitial lung disease: review of the literature, proposal for a preliminary algorithm, and clinical application to cases. Arthritis Res Ther. 2021;23:212. https:\/\/doi.org\/10.1186\/s13075-021-02586-9.","journal-title":"Arthritis Res Ther"},{"key":"389_CR26","doi-asserted-by":"publisher","first-page":"105407","DOI":"10.1016\/j.jbspin.2022.105407","volume":"89","author":"M Gutierrez","year":"2022","unstructured":"Gutierrez M, Ruta S, Clavijo-Cornejo D, Fuentes-Moreno G, Reyes-Long S, Bertolazzi C. The emerging role of ultrasound in detecting interstitial lung disease in patients with rheumatoid arthritis. Joint Bone Spine. 2022;89:105407. https:\/\/doi.org\/10.1016\/j.jbspin.2022.105407.","journal-title":"Joint Bone Spine"},{"key":"389_CR27","doi-asserted-by":"publisher","first-page":"e067434","DOI":"10.1136\/bmjopen-2022-067434","volume":"12","author":"BK Sof\u00edud\u00f3ttir","year":"2022","unstructured":"Sof\u00edud\u00f3ttir BK, Harders SMW, Lage-Hansen PR, Christensen R, Munk HL, Sorensen GL, et al. Using thoracic ultrasound to detect interstitial lung disease in patients with rheumatoid arthritis: a protocol for the diagnostic test accuracy AURORA study. BMJ Open. 2022;12:e067434. https:\/\/doi.org\/10.1136\/bmjopen-2022-067434.","journal-title":"BMJ Open"},{"key":"389_CR28","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1093\/rheumatology\/keq035","volume":"49","author":"G Koduri","year":"2010","unstructured":"Koduri G, Norton S, Young A, Cox N, Davies P, Devlin J, et al. Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology (Oxford). 2010;49:1483\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/keq035.","journal-title":"Rheumatology (Oxford)"},{"key":"389_CR29","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1801562","volume":"379","author":"PA Juge","year":"2018","unstructured":"Juge PA, Lee JS, Ebstein E, Furukawa H, Dobrinskikh E, Gazal S, et al. MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease. N Engl J Med. 2018;379:2209\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1801562.","journal-title":"N Engl J Med"},{"key":"389_CR30","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1002\/art.40904","volume":"71","author":"JA Sparks","year":"2019","unstructured":"Sparks JA, He X, Huang J, Fletcher EA, Zaccardelli A, Friedlander HM, et al. Rheumatoid arthritis disease activity predicting incident clinically apparent rheumatoid arthritis-associated interstitial lung disease: a prospective cohort study. Arthritis Rheumatol. 2019;71:1472\u201382. https:\/\/doi.org\/10.1002\/art.40904.","journal-title":"Arthritis Rheumatol"},{"key":"389_CR31","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3899\/jrheum.200863","volume":"48","author":"VL Kronzer","year":"2021","unstructured":"Kronzer VL, Huang W, Dellaripa PF, Huang S, Feathers V, Lu B, et al. Lifestyle and clinical risk factors for incident rheumatoid arthritis-associated interstitial lung disease. J Rheumatol. 2021;48:656\u201363. https:\/\/doi.org\/10.3899\/jrheum.200863.","journal-title":"J Rheumatol"},{"key":"389_CR32","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1002\/art.42162","volume":"74","author":"PA Juge","year":"2022","unstructured":"Juge PA, Granger B, Debray MP, Ebstein E, Louis-Sidney F, Kedra J, et al. A risk score to detect subclinical rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol. 2022;74:1755\u201365. https:\/\/doi.org\/10.1002\/art.42162.","journal-title":"Arthritis Rheumatol"},{"key":"389_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13075-023-03024-8","volume":"25","author":"H Kim","year":"2023","unstructured":"Kim H, Cho SK, Song YJ, Kang J, Jeong SA, Kim HW, et al. Clinical characteristics of rheumatoid arthritis patients with interstitial lung disease: baseline data of a single-center prospective cohort. Arthritis Res Ther. 2023;25:43. https:\/\/doi.org\/10.1186\/s13075-023-03024-8.","journal-title":"Arthritis Res Ther"},{"key":"389_CR34","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s13075-015-0835-7","volume":"17","author":"JR Curtis","year":"2015","unstructured":"Curtis JR, Sarsour K, Napalkov P, Costa LA, Schulman KL. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor \u03b1 agents, a retrospective cohort study. Arthritis Res Ther. 2015;17:319. https:\/\/doi.org\/10.1186\/s13075-015-0835-7.","journal-title":"Arthritis Res Ther"},{"key":"389_CR35","doi-asserted-by":"publisher","first-page":"e233640","DOI":"10.1001\/jamanetworkopen.2023.3640","volume":"6","author":"MC Baker","year":"2023","unstructured":"Baker MC, Liu Y, Lu R, Lin J, Melehani J, Robinson WH. Incidence of interstitial lung disease in patients with rheumatoid arthritis treated with biologic and targeted synthetic disease-modifying antirheumatic drugs. JAMA Netw Open. 2023;6:e233640. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.3640.","journal-title":"JAMA Netw Open"},{"key":"389_CR36","first-page":"843","volume":"82","author":"P Dieud\u00e9","year":"2023","unstructured":"Dieud\u00e9 P, Sparks J, Fischer A, Chen L, Lozenski K, Dahan S, et al. Incidence rates of interstitial lung disease among patients with rheumatoid arthritis treated with abatacept: a post hoc pooled analysis from a compendium of clinical trials. Ann Rheum Dis. 2023;82:843. (abstract).","journal-title":"Ann Rheum Dis"},{"key":"389_CR37","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315\u201324. https:\/\/doi.org\/10.1002\/art.1780310302.","journal-title":"Arthritis Rheum"},{"key":"389_CR38","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580\u20138. https:\/\/doi.org\/10.1136\/ard.2010.138461.","journal-title":"Ann Rheum Dis"},{"key":"389_CR39","first-page":"2410","volume":"32","author":"F Wolfe","year":"2005","unstructured":"Wolfe F, Michaud K, Pincus T. A composite disease activity scale for clinical practice, observational studies, and clinical trials: the patient activity scale (PAS\/PAS-II). J Rheumatol. 2005;32:2410\u20135.","journal-title":"J Rheumatol"},{"key":"389_CR40","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.3899\/jrheum.080182","volume":"35","author":"T Pincus","year":"2008","unstructured":"Pincus T, Swearingen CJ, Bergman M, Yazici Y. RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories. J Rheumatol. 2008;35:2136\u201347. https:\/\/doi.org\/10.3899\/jrheum.080182.","journal-title":"J Rheumatol"},{"key":"389_CR41","doi-asserted-by":"publisher","first-page":"R796","DOI":"10.1186\/ar1740","volume":"7","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, Smolen JS. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7:R796\u2013806. https:\/\/doi.org\/10.1186\/ar1740.","journal-title":"Arthritis Res Ther"},{"key":"389_CR42","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, van\u2019t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight\u2010joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44\u20138. https:\/\/doi.org\/10.1002\/art.1780380107.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"389_CR43","first-page":"151","volume":"62","author":"J Fransen","year":"2003","unstructured":"Fransen J, Welsing P, de Keijzer R, van Riel P. Disease activity scores using C-reactive protein: CRP may replace ESR in the assessment of RA disease activity. Ann Rheum Dis. 2003;62(Suppl 1):151.","journal-title":"Ann Rheum Dis"},{"key":"389_CR44","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","volume":"42","author":"JS Smolen","year":"2003","unstructured":"Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003;42:244\u201357. https:\/\/doi.org\/10.1093\/rheumatology\/keg072.","journal-title":"Rheumatology (Oxford)"},{"key":"389_CR45","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/S2213-2600(17)30433-2","volume":"6","author":"DA Lynch","year":"2018","unstructured":"Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby TV, Galvin JR, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med. 2018;6:138\u201353. https:\/\/doi.org\/10.1016\/S2213-2600(17)30433-2.","journal-title":"Lancet Respir Med"},{"key":"389_CR46","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1002\/1529-0131(199910)42:10<2220::AID-ANR26>3.0.CO;2-5","volume":"42","author":"T Pincus","year":"1999","unstructured":"Pincus T, Swearingen C, Wolfe F. Toward a multidimensional Health Assessment Questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological status in the patient-friendly health assessment questionnaire format. Arthritis Rheum. 1999;42:2220\u201330. https:\/\/doi.org\/10.1002\/1529-0131(199910)42:10%3C2220::AID-ANR26%3E3.0.CO;2-5.","journal-title":"Arthritis Rheum"},{"key":"389_CR47","unstructured":"QualityMetric Incorporated. The SF-36v2\u00ae Health Survey. https:\/\/www.qualitymetric.com\/health-surveys\/the-sf-36v2-health-survey. Accessed 16 June 2023."},{"key":"389_CR48","unstructured":"Medical Research Council. Modified Medical Research Council (mMRC) dyspnoea scale. Version developed in 1986. https:\/\/www.ukri.org\/councils\/mrc\/facilities-and-resources\/find-an-mrc-facility-or-resource\/mrc-dyspnoea-scale. Accessed 16 June 2023."},{"key":"389_CR49","doi-asserted-by":"publisher","first-page":"00145","DOI":"10.1183\/23120541.00145-2020","volume":"7","author":"J Swigris","year":"2021","unstructured":"Swigris J, Cutts K, Male N, Baldwin M, Rohr KB, Bushnell DM. The living with pulmonary fibrosis questionnaire in progressive fibrosing interstitial lung disease. ERJ Open Res. 2021;7:00145\u20132020. https:\/\/doi.org\/10.1183\/23120541.00145-2020.","journal-title":"ERJ Open Res"},{"key":"389_CR50","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-16399-0","volume-title":"Clinical prediction models. A practical approach to development, validation, and updating","author":"EW Steyerberg","year":"2019","unstructured":"Steyerberg EW. Clinical prediction models. A practical approach to development, validation, and updating. 2nd ed. Switzerland: Springer Cham; 2019.","edition":"2"},{"key":"389_CR51","doi-asserted-by":"publisher","first-page":"55","DOI":"10.7326\/M14-0697","volume":"162","author":"GS Collins","year":"2015","unstructured":"Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med. 2015;162:55\u201363. https:\/\/doi.org\/10.7326\/M14-0697.","journal-title":"Ann Intern Med"},{"key":"389_CR52","doi-asserted-by":"publisher","first-page":"m441","DOI":"10.1136\/bmj.m441","volume":"368","author":"RD Riley","year":"2020","unstructured":"Riley RD, Ensor J, Snell KIE, Harrell FE Jr, Martin GP, Reitsma JB, et al. Calculating the sample size required for developing a clinical prediction model. BMJ. 2020;368:m441. https:\/\/doi.org\/10.1136\/bmj.m441.","journal-title":"BMJ"},{"key":"389_CR53","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.reuma.2019.05.007","volume":"17","author":"F Paulin","year":"2021","unstructured":"Paulin F, Doyle TJ, Mercado JF, Fassola L, Fern\u00e1ndez M, Caro F, et al. Development of a risk indicator score for the identification of interstitial lung disease in patients with rheumatoid arthritis. Reumatol Clin (Engl Ed). 2021;17:207\u201311. https:\/\/doi.org\/10.1016\/j.reuma.2019.05.007.","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"389_CR54","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.reumae.2021.12.003","volume":"19","author":"J Narv\u00e1ez","year":"2023","unstructured":"Narv\u00e1ez J, Aburto M, Seoane-Mato D, Bonilla G, Acosta O, Candelas G, et al. Screening criteria for interstitial lung disease associated to rheumatoid arthritis: expert proposal based on Delphi methodology. Reumatol Clin (Engl Ed). 2023;19:74\u201381. https:\/\/doi.org\/10.1016\/j.reumae.2021.12.003.","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"389_CR55","doi-asserted-by":"publisher","first-page":"823669","DOI":"10.3389\/fimmu.2022.823669","volume":"13","author":"J Xue","year":"2022","unstructured":"Xue J, Hu W, Wu S, Wang J, Chi S, Liu X. Development of a risk nomogram model for identifying interstitial lung disease in patients with rheumatoid arthritis. Front Immunol. 2022;13:823669. https:\/\/doi.org\/10.3389\/fimmu.2022.823669.","journal-title":"Front Immunol"},{"key":"389_CR56","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s00296-023-05313-6","volume":"43","author":"GM Koduri","year":"2023","unstructured":"Koduri GM, Podlasek A, Pattapola S, Zhang J, Laila D, Nandagudi A, et al. Four-factor risk score for the prediction of interstitial lung disease in rheumatoid arthritis. Rheumatol Int. 2023;43:1515\u201323. https:\/\/doi.org\/10.1007\/s00296-023-05313-6.","journal-title":"Rheumatol Int"},{"key":"389_CR57","doi-asserted-by":"publisher","unstructured":"Wheeler AM, Baker JF, Riley T, Yang Y, Roul P, Wysham KD, et al. Development and internal validation of a clinical and genetic risk score for rheumatoid arthritis-associated interstitial lung disease. Rheumatology (Oxford). 2024;keae001. https:\/\/doi.org\/10.1093\/rheumatology\/keae001.","DOI":"10.1093\/rheumatology\/keae001"},{"key":"389_CR58","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3899\/jrheum.171315","volume":"46","author":"K Raimundo","year":"2019","unstructured":"Raimundo K, Solomon JJ, Olson AL, Kong AM, Cole AL, Fischer A, Swigris JJ. Rheumatoid arthritis-interstitial lung disease in the United States: prevalence, incidence, and healthcare costs and mortality. J Rheumatol. 2019;46:360\u20139. https:\/\/doi.org\/10.3899\/jrheum.171315.","journal-title":"J Rheumatol"},{"key":"389_CR59","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1148\/radiol.2321030174","volume":"232","author":"N Tanaka","year":"2004","unstructured":"Tanaka N, Kim JS, Newell JD, Brown KK, Cool CD, Meehan R, et al. Rheumatoid arthritis-related lung diseases: CT findings. Radiology. 2004;232:81\u201391. https:\/\/doi.org\/10.1148\/radiol.2321030174.","journal-title":"Radiology"},{"key":"389_CR60","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.rmed.2017.11.013","volume":"134","author":"HM Nurmi","year":"2018","unstructured":"Nurmi HM, Kettunen HP, Suoranta SK, Purokivi MK, K\u00e4rkk\u00e4inen MS, Selander TA, et al. Several high-resolution computed tomography findings associate with survival and clinical features in rheumatoid arthritis-associated interstitial lung disease. Respir Med. 2018;134:24\u201330. https:\/\/doi.org\/10.1016\/j.rmed.2017.11.013.","journal-title":"Respir Med"},{"key":"389_CR61","doi-asserted-by":"publisher","first-page":"e17088","DOI":"10.1097\/MD.0000000000017088","volume":"98","author":"F Salaffi","year":"2019","unstructured":"Salaffi F, Carotti M, Di Carlo M, Tardella M, Giovagnoni A. High-resolution computed tomography of the lung in patients with rheumatoid arthritis: prevalence of interstitial lung disease involvement and determinants of abnormalities. Med (Baltim). 2019;98:e17088. https:\/\/doi.org\/10.1097\/MD.0000000000017088.","journal-title":"Med (Baltim)"},{"key":"389_CR62","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1183\/13993003.00357-2015","volume":"47","author":"JJ Solomon","year":"2016","unstructured":"Solomon JJ, Chung JH, Cosgrove GP, Demoruelle MK, Fernandez-Perez ER, Fischer A, et al. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2016;47:588\u201396. https:\/\/doi.org\/10.1183\/13993003.00357-2015.","journal-title":"Eur Respir J"},{"key":"389_CR63","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.rmed.2013.05.002","volume":"107","author":"JJ Solomon","year":"2013","unstructured":"Solomon JJ, Ryu JH, Tazelaar HD, Myers JL, Tuder R, Cool CD, et al. Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Respir Med. 2013;107:1247\u201352. https:\/\/doi.org\/10.1016\/j.rmed.2013.05.002.","journal-title":"Respir Med"},{"key":"389_CR64","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1111\/resp.13848","volume":"25","author":"HC Kim","year":"2020","unstructured":"Kim HC, Lee JS, Lee EY, Ha YJ, Chae EJ, Han M, et al. Risk prediction model in rheumatoid arthritis-associated interstitial lung disease. Respirology. 2020;25:1257\u201364. https:\/\/doi.org\/10.1111\/resp.13848.","journal-title":"Respirology"},{"key":"389_CR65","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1183\/09031936.00092309","volume":"35","author":"EJ Kim","year":"2010","unstructured":"Kim EJ, Elicker BM, Maldonado F, Webb WR, Ryu JH, Van Uden JH, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35:1322\u20138. https:\/\/doi.org\/10.1183\/09031936.00092309.","journal-title":"Eur Respir J"},{"key":"389_CR66","doi-asserted-by":"publisher","first-page":"4702","DOI":"10.1093\/rheumatology\/keac184","volume":"61","author":"JH Oh","year":"2022","unstructured":"Oh JH, Kim GHJ, Cross G, Barnett J, Jacob J, Hong S, Song JW. Automated quantification system predicts survival in rheumatoid arthritis-associated interstitial lung disease. Rheumatology (Oxford). 2022;61:4702\u201310. https:\/\/doi.org\/10.1093\/rheumatology\/keac184.","journal-title":"Rheumatology (Oxford)"},{"key":"389_CR67","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1159\/000502551","volume":"98","author":"C Hyldgaard","year":"2019","unstructured":"Hyldgaard C, Ellingsen T, Hilberg O, Bendstrup E. Rheumatoid arthritis-associated interstitial lung disease: clinical characteristics and predictors of mortality. Respiration. 2019;98:455\u201360. https:\/\/doi.org\/10.1159\/000502551.","journal-title":"Respiration"},{"key":"389_CR68","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1093\/rheumatology\/kead027","volume":"62","author":"SH Chang","year":"2023","unstructured":"Chang SH, Lee JS, Ha YJ, Kim MU, Park CH, Lee JS, et al. Lung function trajectory of rheumatoid arthritis-associated interstitial lung disease. Rheumatology (Oxford). 2023;62:3014\u201324. https:\/\/doi.org\/10.1093\/rheumatology\/kead027.","journal-title":"Rheumatology (Oxford)"},{"key":"389_CR69","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/art.39971","volume":"69","author":"JA Zamora-Legoff","year":"2017","unstructured":"Zamora-Legoff JA, Krause ML, Crowson CS, Ryu JH, Matteson EL. Progressive decline of lung function in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol. 2017;69:542\u20139. https:\/\/doi.org\/10.1002\/art.39971.","journal-title":"Arthritis Rheumatol"},{"key":"389_CR70","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3390\/jcm10040874","volume":"10","author":"N Mena-V\u00e1zquez","year":"2021","unstructured":"Mena-V\u00e1zquez N, Rojas-Gimenez M, Romero-Barco CM, Manrique-Arija S, Francisco E, Aguilar-Hurtado MC, et al. Predictors of progression and mortality in patients with prevalent rheumatoid arthritis and interstitial lung disease: a prospective cohort study. J Clin Med. 2021;10:874. https:\/\/doi.org\/10.3390\/jcm10040874.","journal-title":"J Clin Med"},{"key":"389_CR71","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1093\/rheumatology\/keaa621","volume":"59","author":"C Fern\u00e1ndez-D\u00edaz","year":"2020","unstructured":"Fern\u00e1ndez-D\u00edaz C, Casta\u00f1eda S, Melero-Gonz\u00e1lez RB, Ortiz-Sanju\u00e1n F, Juan-Mas A, Carrasco-Cubero C, et al. Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients. Rheumatology (Oxford). 2020;59:3906\u201316. https:\/\/doi.org\/10.1093\/rheumatology\/keaa621.","journal-title":"Rheumatology (Oxford)"},{"key":"389_CR72","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.semarthrit.2020.08.008","volume":"50","author":"J Narv\u00e1ez","year":"2020","unstructured":"Narv\u00e1ez J, Robles-P\u00e9rez A, Molina-Molina M, Vicens-Zygmunt V, Luburich P, Ya\u00f1ez MA, et al. Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive rheumatoid arthritis-related interstitial lung disease. Semin Arthritis Rheum. 2020;50:902\u201310. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.08.008.","journal-title":"Semin Arthritis Rheum"},{"key":"389_CR73","doi-asserted-by":"publisher","first-page":"175346662211353","DOI":"10.1177\/17534666221135314","volume":"16","author":"K Kim","year":"2022","unstructured":"Kim K, Woo A, Park Y, Yong SH, Lee SH, Lee SH, et al. Protective effect of methotrexate on lung function and mortality in rheumatoid arthritis-related interstitial lung disease: a retrospective cohort study. Ther Adv Respir Dis. 2022;16:17534666221135314. https:\/\/doi.org\/10.1177\/17534666221135314.","journal-title":"Ther Adv Respir Dis"},{"key":"389_CR74","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.chest.2022.11.035","volume":"163","author":"SM Matson","year":"2023","unstructured":"Matson SM, Baqir M, Moua T, Marll M, Kent J, Iannazzo NS, et al. Treatment outcomes for rheumatoid arthritis-associated interstitial lung disease: a real-world, multisite study of the impact of immunosuppression on pulmonary function trajectory. Chest. 2023;163:861\u20139.","journal-title":"Chest"},{"key":"389_CR75","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381:1718\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1908681.","journal-title":"N Engl J Med"},{"key":"389_CR76","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1007\/s10067-023-06623-7","volume":"42","author":"EL Matteson","year":"2023","unstructured":"Matteson EL, Aringer M, Burmester GR, Mueller H, Moros L, Kolb M. Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial. Clin Rheumatol. 2023;42:2311\u201319. https:\/\/doi.org\/10.1007\/s10067-023-06623-7.","journal-title":"Clin Rheumatol"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-024-00389-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-024-00389-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-024-00389-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T04:08:30Z","timestamp":1716264510000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcrheumatol.biomedcentral.com\/articles\/10.1186\/s41927-024-00389-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["389"],"URL":"https:\/\/doi.org\/10.1186\/s41927-024-00389-4","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,21]]},"assertion":[{"value":"7 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Advarra Institutional Review Board has approved the study protocol (Pro00071380). All participants will provide written informed consent prior to entering the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JAS reports grant\/research support from Bristol Myers Squibb; and has served as a consultant for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Gilead, Inova Diagnostics, Janssen, Optum, Pfizer, ReCor. PD reports grant\/research support from Bristol Myers Squibb, Chugai, Galapagos, Pfizer; fees for speaking from AbbVie, BI, Bristol Myers Squibb, Galapagos, Janssen, Pfizer; has served as a consultant for AbbVie, BI, Bristol Myers Squibb, Galapagos, Janssen, Novartis, Pfizer; and has served as an advisor or review panel member for Boehringer Ingelheim, Bristol Myers Squibb, Pfizer. A-MH-V reports grant\/research support from Boehringer Ingelheim and Janssen; fees for speaking from Boehringer Ingelheim, Janssen, Medscape, Roche; has served as a consultant for Arxx Therapeutics, Boehringer Ingelheim, Genentech, Janssen, Medscape, Roche; and has received support for travel from Boehringer Ingelheim, Medscape, Roche. GRB has served as a consultant for and received fees for speaking from AbbVie, Bristol Myers Squibb, Boehringer Ingelheim, Galapagos, Lilly, Pfizer, Sanofi; and has received fees for speaking from Chugai. SLFW reports grant\/research support from Boehringer Ingelheim and Galapagos; fees for speaking from Boehringer Ingelheim, Galapagos, Roche; and has served as a consultant for Boehringer Ingelheim, Galapagos, OncoArendi Therapeutics, PureTech, Roche, Sanofi-Genzyme. MK reports grant\/research support, fees for speaking and consultancy fees from Boehringer Ingelheim and Roche. CS, SS and MA are employees of Boehringer Ingelheim. PE reports grant\/research support from AbbVie, Bristol Myers Squibb, Lilly, Novartis, Samsung and has served as a consultant for AbbVie, Bristol Myers Squibb, Boehringer Ingelheim, Galapagos, Gilead, Janssen, Lilly, Novartis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}